Key facts
- This page summarizes PURA VIDA INVESTMENTS, LLC's Form 4 filing for Oncocyte Corp (OCX).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 18 Apr 2023, 19:11.
PURA VIDA INVESTMENTS, LLC - 14 Apr 2023 Form 4 Insider Report for Oncocyte Corp (OCX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- OCX
- Reported as of
- 14 Apr 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Apr 2023, 19:11:55 UTC
- Prior SEC filing
- 07 Apr 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Efrem Kamen, Managing Member of Pura Vida Investments, LLC
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
PURA VIDA INVESTMENTS, LLC filed Form 4 for Oncocyte Corp (OCX) on 18 Apr 2023.
Change
- Previous filing in this sequence was filed on 07 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OCX
holding
Derivative
Warrant to purchase common stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 517,245
- Date
- 14 Apr 2023
- Ownership
- By the Managed Accounts
- Underlying class
- Common Stock
- Underlying amount
- 517,245
- Exercise price
- $1.53
- Footnotes
- F1, F2, F3
OCX
holding
Derivative
Warrant to purchase common stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 832,949
- Date
- 14 Apr 2023
- Ownership
- By Pura Vida Master Fund, Ltd.
- Underlying class
- Common Stock
- Underlying amount
- 832,949
- Exercise price
- $1.53
- Footnotes
- F1, F2, F3
OCX
holding
Derivative
Warrant to purchase common stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 383,976
- Date
- 14 Apr 2023
- Ownership
- By Pura Vida X Fund LP
- Underlying class
- Common Stock
- Underlying amount
- 383,976
- Exercise price
- $1.53
- Footnotes
- F1, F2, F3
OCX
holding
Derivative
Warrant to purchase common stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 690,719
- Date
- 14 Apr 2023
- Ownership
- By the Retirement Trust
- Underlying class
- Common Stock
- Underlying amount
- 690,719
- Exercise price
- $1.53
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
PURA VIDA INVESTMENTS, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
As of the reporting date, the Warrants are subject to an ownership blocker provision that prevents the Reporting Persons from exercising the Warrants if they would have voting and dispositive power for more than 9.99% of the common stock outstanding following such exercise.
Footnote F2
Securities reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust") and certain separately managed account(s) (the "Managed Accounts" and collectively, the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.
Footnote F3
By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.